In cancer, the inappropriate expression or activity of specialised receptors, such as integrins and cadherins, actively promotes cancer progression. We focus on understanding this process with a view to identifying new molecular therapeutic targets.
We are working to improve the understanding of the molecular regulation of tumour angiogenesis and identify ways to target angiogenesis to improve treatment for patients.
We are working to further understand the molecular basis for blood cancers, identify targets for novel targeted therapies and identify biomarkers of prognosis and response to treatment.
Our research focuses on understanding the basic molecular biology of breast cancer through to epidemiological studies on the different molecular sub-types and their incidence.
Bioinformatics enables cancer researchers to manage, analyse, mine and understand the currently accumulated, valuable, high-throughput data.
We are developing experimental treatments that can target cancers that have become resistant to standard therapies, with a particular focus on the development of gene therapy strategies to target pancreatic, prostate and ovarian cancers.
Imaging plays a crucial role in the clinical management of patients with cancer. It can provide essential information on the localisation and staging of disease as well as on an individual's prognosis and response to therapy.
We conduct research into the prevention of cancer with particular focus on preventive therapy and screening. We focus on identifying and validating interventions for reducing the risk of cancer, and finding effective, minimally toxic prophylactic interventions.
We study how to optimise the efficacy and cost-effectiveness, and minimise the harms of screening programmes. We research technologies to improve existing screening programmes.
Targeting cell signalling has proven extremely successful in cancer treatment. Pathways that govern how cells proliferate, move, survive and differentiate represent key targets in cancer biology.
The field of cancer metabolism has been rapidly evolving in the last decade. Changes in the metabolism of sugars, lipids, amino acids and other sources of energy are now investigated as part of the phenomenon of metabolic rewiring in cancer.
We are working to improve our knowledge of the biology of these diseases, and identify critical genes for novel therapies.
Our researchers are combining both basic molecular biology and clinical research to advance our understanding and treatment of lung cancer.
Around 90% of cancer mortality is attributable to invasion and metastasis. Characterisation of the molecules driving tumour dissemination may provide possible ways to block the process and aid in the identification of potential therapeutic targets.
Our research is focused on understanding the genetic evolution and malignant transformation of common precursor conditions, such as Barrett’s oesophagus.
Our focus is on translational research, aimed at developing new treatments for women with ovarian cancer.
Our research is focused on understanding the molecular basis of pancreatic cancer initiation, progression, and the development of new therapeutic strategies to improve outcome.
We are working to identify factors that influence both prostate cancer progression and the therapeutic response, to improve treatment and inform the development of novel therapies.